VIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngine
VIVUS (NASDAQ:VVUS) was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a report issued on Friday.
Shares of VIVUS (NASDAQ VVUS) traded down $0.01 during trading on Friday, hitting $0.63. 390,008 shares of the stock traded hands, compared to its average volume of 718,693. VIVUS has a fifty-two week low of $0.61 and a fifty-two week high of $1.47. The company has a debt-to-equity ratio of 643.86, a quick ratio of 7.09 and a current ratio of 7.47. The firm has a market cap of $67.22, a PE ratio of 1.88 and a beta of 0.82.
VIVUS (NASDAQ:VVUS) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.07. VIVUS had a net margin of 26.71% and a return on equity of 344.23%. The business had revenue of $15.19 million during the quarter, compared to analysts’ expectations of $16.00 million. During the same quarter in the prior year, the business posted ($0.09) EPS. The company’s revenue for the quarter was up 13.8% on a year-over-year basis. analysts expect that VIVUS will post -0.32 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “VIVUS (VVUS) Rating Lowered to Strong Sell at ValuEngine” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/12/01/vivus-vvus-rating-lowered-to-strong-sell-at-valuengine.html.
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.